Application of cordyceps guangdongensis sporocarp polysaccharide in preparation of product for treating and improving diabetic nephropathy

Abstract

The invention discloses an application of cordyceps guangdongensis sporocarp polysaccharide in preparation of a product for treating and improving diabetic nephropathy. Experimental results show that the cordyceps guangdongensis sporocarp polysaccharide can treat and improve the diabetic nephropathy, improve the renal function, reduce the levels of serum urea nitrogen and serum creatinine, and reduce the level of uremia toxin indolesulfuric acid phenol in the plasma of diabetic mice; kidney inflammation is improved, and mRNA expression of IL-6, TNF-alpha, IL-1beta and MCP-1 in the kidney is reduced; the oxidative stress and fibrosis of the kidney are inhibited, and the mRNA expression of Rac1, keap1, Ncf2 and Nsf11c of the kidney is reduced; the abundance of pathogenic bacteria in intestinal tracts and kidneys is reduced, and the pathogenic bacteria are mainly Escherichia.

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and specifically relates to the application of Guangdong Cordyceps sinensis fruiting body polysaccharide in the preparation of products for treating and improving diabetic nephropathy. Background Art

[0002] Diabetes is a chronic disease characterized by hyperglycemia caused by insufficient insulin secretion or impaired insulin utilization. Type 2 diabetes is the most common type of diabetes, accounting for about 90% of the world's diabetes population. The etiology of type 2 diabetes is not fully understood, but it is closely related to overweight, obesity, aging, race and family history. As the disease progresses, it will further cause diabetic complications such as diabetic nephropathy, retinopathy, neuropathy, peripheral arterial disease and foot ulcers. Diabetic kidney disease (DKD) is one of the most common and most serious microvascular complications in diabetic patients and the main cause of end-stage kidney disease (ESKD). About 30%-40% of diabetic patients worldwide have kidney damage. The pathogenesis of DKD is complex, involving the interaction of multiple factors such as impaired glucose metabolism, changes in renal hemodynamics, abnormal cytokine expression, oxidative stress, renal tissue inflammation and genetics. Currently, there is a lack of effective drugs to improve and treat DKD. Common clinical treatments mainly include controlling blood sugar, blood pressure and blood lipids. When DKD develops to a certain stage, it needs to be treated by hemodialysis, peritoneal dialysis and kidney transplantation. There is an urgent need to improve the understanding of the pathogenesis of DKD and develop new and effective treatments and strategies to slow down the development of DKD.

[0003] Edible and medicinal fungi are rich in polysaccharides, proteins, triterpenes and polyphenols, etc., and have health benefits such as anti-oxidation, cholesterol-lowering, anti-hypertension, anti-inflammatory, liver protection, anti-virus and anti-diabetes. Guangdong Cordyceps (Cordyceps guangdongensis) belongs to the Ascomycota, Ophiocordicipitaceae, Tolypocladium, and is a unique Cordyceps resource in my country. It was approved as a new resource food in 2013 (Ministry of Health Announcement No. 1 of 2013). Guangdong Cordyceps is very similar to the active ingredients of wild Cordyceps sinensis, including cordycepic acid, adenosine, Cordyceps polysaccharides, Cordyceps peptides, flavonoids, alkaloids, organic acids, vitamins and trace elements. It has pharmacological activities such as anti-fatigue, anti-oxidation, anti-virus, improvement of chronic bronchitis and improvement of immunity. At present, there is no report on the improvement of diabetic nephropathy related aspects of the fruiting body polysaccharide components of Guangdong Cordyceps. Summary of the invention

[0004] The purpose of the present invention is to provide a new medical application of Cordyceps fruiting body polysaccharide.

[0005] The new medical use of Cordyceps fruiting body polysaccharide provided by the present invention is: use of Cordyceps fruiting body polysaccharide in preparing products for treating and improving diabetic nephropathy.

[0006] The Cordyceps fruiting body polysaccharide may specifically be Guangdong Cordyceps fruiting body polysaccharide.

[0007] The Cordyceps fruiting body polysaccharide is prepared by a method comprising the following steps:

[0008] The Cordyceps fruiting body is dried, crushed, extracted with anhydrous ethanol under reflux, filtered, the residue after ethanol extraction is collected, dried, extracted with distilled water under reflux, the extract is collected, concentrated, and protein is removed by Sevag reagent. The obtained protein-removed extract is purified by ethanol graded precipitation to obtain Cordyceps fruiting body polysaccharide.

[0009] In the above method, the Cordyceps fruiting body can specifically be the Cordyceps sinensis fruiting body;

[0010] The drying is carried out in a blast drying oven at 50-60°C;

[0011] The ratio of Cordyceps sinensis fruiting body to anhydrous ethanol can be 1kg:10-30L, specifically 1kg:10L;

[0012] Reflux extraction with anhydrous ethanol for multiple times, specifically 3 times, each time for 0.5h-3.0h, specifically 1.0h;

[0013] The ratio of Cordyceps fruiting body residue to distilled water can be 1kg:20-50L;

[0014] Reflux extraction with distilled water for multiple times, specifically 3 times, each time for 0.5h-3.0h, specifically 2h;

[0015] The operation of using Sevag reagent to remove protein is as follows: add chloroform-n-butanol mixed solution to the extract (crude polysaccharide solution), shake it thoroughly to denature the free protein into insoluble substances, remove the precipitate by centrifugation, and collect the concentrated solution.

[0016] The ethanol graded precipitation comprises the following operations:

[0017] Adding anhydrous ethanol to the obtained protein-removed extract to a volume concentration of 30%, subjecting the mixture to alcohol precipitation overnight, centrifuging, collecting the precipitate and the supernatant, and obtaining crude polysaccharide 1 and supernatant 1;

[0018] Adding anhydrous ethanol to the supernatant 1 to a final ethanol concentration of 50% by volume, subjecting the mixture to alcohol precipitation overnight, centrifuging, collecting the precipitate and the supernatant to obtain crude polysaccharide 2 and supernatant 2;

[0019] Anhydrous ethanol was added to the supernatant 2 to a final ethanol concentration of 75% by volume, and the mixture was precipitated overnight. The mixture was centrifuged, and the precipitate and the supernatant were collected to obtain crude polysaccharide 3 and supernatant 3.

[0020] Collecting 50% ethanol precipitation fraction (crude polysaccharide 2), washing the precipitate with anhydrous ethanol, acetone and anhydrous ether respectively, re-dissolving the precipitate with distilled water, and vacuum freeze-drying to obtain Cordyceps fruiting body polysaccharide CGDP;

[0021] Wherein, the temperature of the alcohol precipitation overnight is 4°C.

[0022] The monosaccharide composition of the obtained cordyceps fruiting body polysaccharide is: calculated by chromatographic peak area, mannose 35-60%, glucose 5-20% and galactose 35-55%.

[0023] In the application, the product may specifically be food and / or medicine;

[0024] The applications include: 1) improving renal function;

[0025] 2) reduced renal inflammation (reduced mRNA expression of IL-6, TNF-α, IL-1β, and MCP-1 in the kidney);

[0026] 3) Inhibits renal oxidative stress and fibrosis (reduces renal mRNA expression of Rac1, keap1, Ncf2, and Nsf11c)

[0027] 4) Reduce the abundance of pathogenic bacteria (mainly Escherichia coli) in the intestines and kidneys.

[0028] The obtained cordyceps fruiting body polysaccharide is a natural, non-toxic and side-effect free edible and medicinal fungus extract, and animal experiments have confirmed that it has an obvious effect of treating and improving diabetic nephropathy.

[0029] The Cordyceps fruiting body polysaccharide can be made into a clinically acceptable oral dosage form with pharmaceutically acceptable adjuvants according to traditional or modern production processes. Such as powder, tea, granules, capsules, tablets, concentrated pills, dripping pills, films, decoctions, oral liquids or oral emulsions, etc. The pharmaceutical adjuvants used can be starch, dextrin, lactose, microcrystalline cellulose, gelatin, sucrose, magnesium stearate, erythritol, xylitol, sorbitol, mannitol, maltitol, isomalt, hydrogenated starch hydrolysate, stevioside, steviolbioside, dihydrochalcone, glycyrrhizin, xylitol, aspartame, alitame, saccharin, sodium cyclamate, acesulfame potassium, sucralose, etc. Clinically, long-term medication is needed, and solid preparations are made for convenient storage, convenient for patients to take, and more suitable for market demand. The preferred dosage form is capsules, granules, and tablets.

[0030] Compared with the prior art, the present invention has the following advantages:

[0031] (1) The Guangdong Cordyceps fruiting body polysaccharide prepared by the present invention can treat and improve diabetic nephropathy, improve renal function, reduce serum urea nitrogen and blood creatinine levels, and reduce the level of uremic toxin indoxylsulfate (IS) in the plasma of diabetic mice; improve renal inflammation, reduce the mRNA expression of IL-6, TNF-α, IL-1β and MCP-1 in the kidney; inhibit renal oxidative stress and fibrosis, and reduce the mRNA expression of Rac1, keap1, Ncf2 and Nsf11c in the kidney; reduce the abundance of pathogenic bacteria in the intestine and kidney, mainly Escherichia coli.

[0032] (2) The preparation method of the Guangdong Cordyceps fruiting body polysaccharide of the present invention is simple and the preparation conditions are mild, which can retain the complete structure and active ingredients of the polysaccharide to the greatest extent.

[0033] Therefore, the research and development of food or drugs for treating and improving diabetic nephropathy using Cordyceps sinensis fruiting body polysaccharides has important clinical significance and scientific value. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is the ion exchange chromatography DEAE-52 separation diagram of the Cordyceps sinensis fruiting body polysaccharide in Example 2 of the present invention;

[0035] Figure 2 The monosaccharide composition spectrum of the fruiting body polysaccharide of Cordyceps sinensis in Example 3 of the present invention;

[0036] Figure 3 The effect of Guangdong Cordyceps polysaccharide CGDP on renal function of diabetic mice in Example 4 of the present invention, wherein A indicates that CGDP can reduce the level of urea nitrogen (BUN) in mouse serum, B indicates that CGDP can reduce the level of blood creatinine (Scr) in mouse serum, and C indicates that CGDP can reduce the level of indole sulfate in mouse plasma;

[0037] Figure 4 The effect of Guangdong Cordyceps polysaccharide CGDP on the renal morphology of diabetic mice in Example 4 of the present invention, wherein A shows that CGDP significantly reduces renal fibrosis in db / db diabetic mice, and B is the renal injury score of each group;

[0038] Figure 5 The effects of Guangdong Cordyceps polysaccharide CGDP on renal inflammation in diabetic mice in Example 4 of the present invention, wherein A, B, and C show that Guangdong Cordyceps polysaccharide CGDP significantly reduces the levels of inflammatory factors in the plasma of db / db diabetic mice, and D shows that Guangdong Cordyceps polysaccharide CGDP reduces the mRNA expression of IL-6, TNF-α, IL-1β and MCP-1 in the kidney;

[0039] Figure 6 The effect of Guangdong Cordyceps polysaccharide CGDP on renal oxidative stress in diabetic mice in Example 4 of the present invention;

[0040] Figure 7 This is the effect of Guangdong Cordyceps polysaccharide CGDP in Example 4 of the present invention on pathogenic bacteria in the kidneys of diabetic mice. DETAILED DESCRIPTION

[0041] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0042] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0043] Example 1

[0044] Preparation method of Guangdong Cordyceps fruiting body polysaccharide

[0045] Fresh Guangdong Cordyceps fruiting bodies were dried in a 50-60°C blast drying oven, and the dried fruiting bodies were crushed with a pulverizer. 2 kg of fruiting bodies were weighed, and 20 L of anhydrous ethanol was added for reflux extraction for 3 times, each time for 1.0 h, to remove alcohol-soluble small molecules, and the precipitate was dried. 1.6 kg of precipitate (residue) was extracted with 40 L of distilled water at 90°C for 2 h, and extracted 3 times in total. The extracts were combined and concentrated to 4 L, and 1.3 L of Sevag reagent (chloroform: n-butanol = 4:1) was added, and the mixture was shaken vigorously for 30 min, and centrifuged at 6000 for 30 min to remove protein precipitates, and repeated 4 times;

[0046] The protein-removed extract obtained above was added with anhydrous ethanol to a volume concentration of 30%, and precipitated at 4°C overnight. The precipitate and the supernatant were collected separately to obtain crude polysaccharide 1 and supernatant 1.

[0047] The supernatant 1 was further added with anhydrous ethanol until the final ethanol concentration was 50%, and the mixture was precipitated at 4°C overnight. The mixture was centrifuged and the precipitate and the supernatant were collected to obtain crude polysaccharide 2 and supernatant 2.

[0048] The supernatant 2 was further added with anhydrous ethanol until the final ethanol concentration was 75% by volume, and the mixture was precipitated at 4°C overnight. The mixture was centrifuged and the precipitate and the supernatant were collected to obtain crude polysaccharide 3 and supernatant 3.

[0049] The 50% ethanol precipitation component (crude polysaccharide 2) was collected, and the precipitate was washed with 500 mL of anhydrous ethanol, acetone and anhydrous ether respectively, and the precipitate was re-dissolved with 200 mL of distilled water and vacuum freeze-dried to obtain 188.6 g of Guangdong Cordyceps fruiting body polysaccharide CGDP.

[0050] Example 2

[0051] Preparation of Cordyceps sinensis fruiting body polysaccharides CGDP1 and CGDP2

[0052] The Guangdong Cordyceps fruiting body polysaccharides CGDP1 and CGDP2 are obtained by secondary purification of the Guangdong Cordyceps fruiting body polysaccharide CGDP obtained in Example 1, and the specific method is as follows:

[0053] Ion exchange chromatography separation and purification: Take 100 mg of Guangdong Cordyceps fruiting body polysaccharide CGDP precipitated with 50% ethanol in Example 1, dissolve it in 2 mL of distilled water, add it to ion exchange chromatography DEAE-52 (2.6*60 cm), elute with 160 mL of distilled water and 160 mL of 0.5 M NaCl solution, respectively, at a flow rate of 0.5 mL / min, collect with an automatic step-by-step collector, detect with a phenol-sulfuric acid method, draw an elution curve, collect and combine the eluents according to the elution curve, dialyze, and vacuum freeze-dry to obtain polysaccharide component 1 (CGDP1) eluted with distilled water and component 2 (CGDP2) eluted with 0.5 M NaCl solution, Figure 1 This is the ion exchange chromatography DEAE-52 separation diagram of Cordyceps sinensis fruiting body polysaccharides.

[0054] Example 3

[0055] Analysis of Monosaccharide Composition of Polysaccharides CGDP1 and CGDP2 from Cordyceps sinensis Fruiting Bodies

[0056] The monosaccharide composition of CGDP1 and CGDP2 polysaccharides from Cordyceps sinensis fruiting body was detected by PMP pre-column derivatization method.

[0057] Acid hydrolysis of polysaccharide samples: Weigh 10 mg of purified CGDP1 and CGDP2 samples, add them into a stoppered test tube, add 2 mL of trifluoroacetic acid (TFA) (4 mol / L) solution and mix well, place at 110 °C for hydrolysis for 2 h, cool to room temperature, repeatedly add methanol and evaporate on a rotary evaporator to remove excess TFA, dissolve the sample with 1 mL of deionized water to obtain a polysaccharide sample hydrolyzate.

[0058] Derivatization of polysaccharide and monosaccharide standard PMP: 5 mg of mannose, galactose, rhamnose, glucose, arabinose, xylose, glucuronic acid and galacturonic acid were respectively fixed to a 25 mL volumetric flask to obtain a mixed sample of monosaccharide standards. Take 100 μL of mixed monosaccharide standards, 50 μL of 0.3 mol / L NaOH solution, and 50 μL of 0.5 mol / L PMP methanol solution and mix them thoroughly, and heat them in a 70 ° C water bath for 30 min. After cooling, add 50 μL of 0.3 mol / L HCl neutralization solution, mix well, add 1 mL of chloroform to extract excess PMP, and discard the lower layer of liquid. Repeat this operation 3 times, centrifuge for 10 min (speed 8000 r / min) and collect the supernatant, filter through a 0.22 μm microporous filter membrane, and set aside. Use the same method to derivatize 100 μL of polysaccharide hydrolysis sample.

[0059] Liquid analysis: Wondasil C18 (250 mm × 4.6 mm, 5 μm) chromatographic column; mobile phase is phosphate buffer solution (pH 6.9)-acetonitrile (85:15); 40 ° C column temperature; 1.0 mL / min flow rate; 20 μL injection volume; 254 nm detection wavelength.

[0060] Experimental results:

[0061] like Figure 2 As shown, the sample hydrolyzed by TFA acid was derivatized with PMP and further analyzed by HPLC. The monosaccharide composition of CGDP1 was mannose, glucose and galactose, accounting for 40.94%, 16.63% and 42.4% respectively. The monosaccharide composition of CGDP2 was mannose, glucose and galactose, accounting for 58.01%, 6.68% and 35.31% respectively.

[0062] Example 4

[0063] Study on the effect of Cordyceps sinensis fruiting body polysaccharide on improving diabetic nephropathy

[0064] The Guangdong Cordyceps fruiting body polysaccharide described in this example is the Guangdong Cordyceps fruiting body polysaccharide CGDP obtained in Example 1.

[0065] SPF Db / db diabetic mice and C57BLKS control mice were purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd., license number: SCXK (Su) 2018-0008.

[0066] 1. Mouse grouping: 30 male 8-week-old SPF-grade db / db diabetic mice and 10 C57BLKS control mice were raised in the Experimental Animal Center of the Institute of Microbiology, Chinese Academy of Sciences, in a temperature environment of 20±2°C and a humidity environment of 55±10%, with 12 / 12h alternating feeding day and night, 5 mice / cage, and mice were free to eat and drink. After acclimatization for 1 week, db / db diabetic mice were randomly divided into 3 groups (model control group, low-dose Guangdong Cordyceps polysaccharide group and high-dose Guangdong Cordyceps polysaccharide group), and C57BLKS was used as a normal control group, with 10 mice in each group.

[0067] 2. Modeling and administration: All mice were fed with conventional feed, and mice in the normal control group (Con) and the model control group (db / db) were gavaged with 200 μL distilled water, the low-dose group (CGDPL) was gavaged with 0.5 g / kg of Guangdong Cordyceps polysaccharide CGDP, and the high-dose group (CGDPH) was gavaged with 1.0 g / kg of Guangdong Cordyceps polysaccharide CGDP. During the experiment, mice were free to eat and drink water. After gavage for 8 weeks, the blood and tissues of the mice were collected, frozen in liquid nitrogen, and stored in a -80°C refrigerator.

[0068] Experimental results:

[0069] 1. Effect of Guangdong Cordyceps Polysaccharide CGDP on Renal Function in Diabetic Mice

[0070] The db / db diabetic mice that had been gavaged with Guangdong Cordyceps polysaccharide CGDP for 8 weeks were fasted for 12 h, and blood was collected from the eye sockets after anesthesia. The plasma was collected and the levels of urea nitrogen and serum creatinine in the mouse plasma were determined using ELISA kits. Figure 3 As shown in Figure 2, CGDP can significantly improve the renal function of db / db diabetic mice and reduce the blood urea nitrogen (BUN) in the serum of mice ( Figure 3 A) and serum creatinine (Scr) ( Figure 3 At the same time, the high-dose group of CGDP can also reduce the level of indole sulfate in the plasma of diabetic nephropathy mice ( Figure 3 Middle C).

[0071] 2. Effect of Guangdong Cordyceps Polysaccharide CGDP on Renal Morphology in Diabetic Mice

[0072] The db / db diabetic mice that had been gavaged with Guangdong Cordyceps polysaccharide CGDP for 8 weeks were fasted for 12 hours, blood was collected from the eye sockets after anesthesia, and the mice were killed by cervical dislocation. The kidney tissue was obtained and the changes in kidney morphology and structure were observed after H&E staining. Figure 4 As shown, CGDP significantly reduced renal fibrosis and renal injury scores in db / db diabetic mice.

[0073] 3. Effect of Guangdong Cordyceps Polysaccharide CGDP on Renal Inflammation in Diabetic Mice

[0074] The db / db diabetic mice gavaged with Guangdong Cordyceps polysaccharide CGDP for 8 weeks were fasted for 12 hours, blood was collected from the eye sockets after anesthesia, and the mice were killed by cervical dislocation. The kidney tissue was obtained and RNA was extracted to quantitatively analyze the expression of related inflammatory factors in the kidney. The levels of inflammatory factors such as interleukin 6 (IL-6), tumor necrosis factor (TNF-α) and interleukin 1β (IL-1β) in mouse plasma were determined by ELISA kits. Figure 5 As shown, Guangdong Cordyceps polysaccharide CGDP significantly reduced the levels of inflammatory factors in the plasma of db / db diabetic mice ( Figure 5 A, B, C). It can also reduce the mRNA of IL-6, TNF-α, IL-1β and MCP-1 in the kidney ( Figure 5 The above results indicate that CGDP can improve renal inflammation in db / db diabetic mice.

[0075] 4. Guangdong Cordyceps polysaccharide CGDP improves renal oxidative stress in db / db diabetic mice

[0076] The db / db diabetic mice that had been gavaged with Guangdong Cordyceps polysaccharide CGDP for 8 weeks were fasted for 12 hours, blood was collected from the eye sockets after anesthesia, and the mice were killed by cervical dislocation. The kidney tissue was obtained, RNA was extracted, and the expression of oxidative stress-related genes in the kidney was quantitatively analyzed. Figure 6 As shown, CGDP significantly reduced the mRNA expression of oxidative stress-related genes Rac1, keap1, Ncf2, and Nsf11c in the kidneys of db / db diabetic mice;

[0077] 5. Guangdong Cordyceps polysaccharide CGDP reduces the abundance of harmful bacteria in the kidneys of db / db diabetic mice. That is, the mouse kidneys were homogenized and plated on LB plates, cultured at 37℃ for 24h, and then counted. Figure 7 As shown, Guangdong Cordyceps polysaccharide CGDP significantly reduced the abundance of pathogenic bacteria in the kidneys of db / db diabetic mice, especially the abundance of Escherichia coli.

[0078] In summary, the present invention aims to study the effect of Cordyceps sinensis fruiting body polysaccharide on diabetic nephropathy in db / db diabetic mice. It shows that Cordyceps sinensis fruiting body polysaccharide improves the renal function of diabetic mice, reduces renal inflammation, improves renal oxidative stress, and reduces the abundance of pathogenic bacteria in the intestine and kidney.

[0079] Guangdong Cordyceps fruiting body polysaccharide shows good efficacy in improving and treating diabetic nephropathy. The present invention provides the use of Guangdong Cordyceps fruiting body polysaccharide in the preparation of food or medicine for treating and improving diabetic nephropathy, providing a new resource for the development of related products in the fields of biomedicine and food.

[0080] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. Application of Cordyceps sinensis fruiting body polysaccharides in the preparation of products for treating and improving diabetic nephropathy.

2. The use according to claim 1, characterized in that: The Cordyceps fruiting body polysaccharide is Guangdong Cordyceps fruiting body polysaccharide.

3. The use according to claim 1 or 2, characterized in that: The Cordyceps fruiting body polysaccharide is prepared by a method comprising the following steps: The Cordyceps fruiting body is dried, crushed, extracted with anhydrous ethanol under reflux, filtered, the residue after ethanol extraction is collected, dried, extracted with distilled water under reflux, the extract is collected, concentrated, protein is removed by Sevag reagent, and the obtained protein-removed extract is purified by ethanol graded precipitation method to obtain Cordyceps fruiting body polysaccharide.

4. The use according to claim 3, characterized in that: The drying temperature is 50-60 o C is carried out in a blast drying oven; The ratio of Cordyceps sinensis fruiting body to anhydrous ethanol is 1kg:10-30L; Reflux extraction with anhydrous ethanol for multiple times, specifically 3 times, each time for 0.5h-3.0h; The ratio of Cordyceps fruiting body residue to distilled water is 1kg:20-50L; The mixture was extracted by reflux with distilled water for multiple times, specifically 3 times, each time for 0.5 h to 3.0 h.

5. The use according to claim 3, characterized in that: The ethanol graded precipitation comprises the following operations: Adding anhydrous ethanol to the obtained protein-removed extract to a volume concentration of 30%, subjecting the mixture to alcohol precipitation overnight, centrifuging, collecting the precipitate and the supernatant, and obtaining crude polysaccharide 1 and supernatant 1; Adding anhydrous ethanol to the supernatant 1 to a final ethanol concentration of 50% by volume, subjecting the mixture to alcohol precipitation overnight, centrifuging, collecting the precipitate and the supernatant to obtain crude polysaccharide 2 and supernatant 2; Anhydrous ethanol was added to the supernatant 2 to a final ethanol concentration of 75% by volume, and the mixture was precipitated overnight. The mixture was centrifuged, and the precipitate and the supernatant were collected to obtain crude polysaccharide 3 and supernatant 3. The 50% ethanol precipitate fraction was collected, and the precipitate was washed with anhydrous ethanol, acetone and anhydrous ether respectively, and the precipitate was re-dissolved with distilled water, and vacuum freeze-dried to obtain Cordyceps sinensis fruiting body polysaccharide CGDP.

6. The use according to any one of claims 1 to 5, characterized in that: The monosaccharide composition of the Cordyceps fruiting body polysaccharide is: based on the chromatographic peak area, mannose 35-60%, glucose 5%-20% and galactose 35%-55%.

7. The use according to any one of claims 1 to 6, characterized in that: The product is a food and / or a medicine.

8. The use according to any one of claims 1 to 7, characterized in that: The applications include: 1) improving renal function; 2) Reduce kidney inflammation; 3) Inhibit renal oxidative stress and fibrosis; 4) Reduce the abundance of pathogenic bacteria in the intestines and kidneys.

9. The use according to claim 8, characterized in that: The pathogenic bacteria are mainly Escherichia coli.

Images